Stroke in patients with acute coronary syndromes

Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial

Kenneth W. Mahaffey, Robert A. Harrington, Maarten L. Simoons, Christopher B. Granger, Carmelo Graffagnino, Mark J. Alberts, Daniel T. Laskowitz, Julie M. Miller, Michael A. Sloan, Lisa G. Berdan, Cynthia M. MacAulay, A. Michael Lincoff, Jaap Deckers, Eric J. Topol, Robert M. Califf

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background - The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates. Methods and Results - We studied the 10 948 patients with acute coronary syndromes without persistent ST-segment elevation who were randomly assigned to placebo or the platelet glycoprotein IIb/IIIa receptor inhibitor eptifibatide in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial to determine stroke fates, stroke types, clinical outcomes in patients with stroke, and independent baseline clinical predictors for nonhemorrhagic stroke. Stroke occurred in 79 (0.7%) patients, with 66 (0.6%) nonhemorrhagic, 6 intracranial hemorrhages, 3 cerebral infarctions with hemorrhagic conversion, and 4 of uncertain cause. There were no differences in stroke rates between patients who received placebo and those assigned high-dose eptifibatide (odds ratios and 95% confidence intervals 0.82 [0.59, 1.14] and 0.70 [0.49, 0.99], respectively). Of the 79 patients with stroke, 17 (22%) died within 30 days, and another 26 (32%) were disabled by hospital discharge or 30 days, whichever came first. Higher heart rate was the most important baseline clinical predictor of nonhemorrhagic stroke, followed by older age, prior anterior myocardial infarction, prior stroke or transient ischemic attack, and diabetes mellitus. These factors were used to develop a simple scoring nomogram that can predict the risk of nonhemorrhagic stroke. Conclusions - Stroke was an uncommon event in patients with acute coronary syndromes in the PURSUIT trial. These strokes are, however, associated with substantial morbidity and mortality rates. The majority of strokes were of nonhemorrhagic causes. Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed. We developed a useful nomogram for assigning baseline nonhemorrhagic stroke risk in this patient population.

Original languageEnglish (US)
Pages (from-to)2371-2377
Number of pages7
JournalCirculation
Volume99
Issue number18
StatePublished - May 11 1999

Fingerprint

Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Unstable Angina
Acute Coronary Syndrome
Stroke
Incidence
Therapeutics
Nomograms
eptifibatide
Intracranial Hemorrhages
Placebos

Keywords

  • Coronary disease
  • Glycoproteins
  • Myocardial infarction
  • Receptors
  • Stroke

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Stroke in patients with acute coronary syndromes : Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial. / Mahaffey, Kenneth W.; Harrington, Robert A.; Simoons, Maarten L.; Granger, Christopher B.; Graffagnino, Carmelo; Alberts, Mark J.; Laskowitz, Daniel T.; Miller, Julie M.; Sloan, Michael A.; Berdan, Lisa G.; MacAulay, Cynthia M.; Lincoff, A. Michael; Deckers, Jaap; Topol, Eric J.; Califf, Robert M.

In: Circulation, Vol. 99, No. 18, 11.05.1999, p. 2371-2377.

Research output: Contribution to journalArticle

Mahaffey, KW, Harrington, RA, Simoons, ML, Granger, CB, Graffagnino, C, Alberts, MJ, Laskowitz, DT, Miller, JM, Sloan, MA, Berdan, LG, MacAulay, CM, Lincoff, AM, Deckers, J, Topol, EJ & Califf, RM 1999, 'Stroke in patients with acute coronary syndromes: Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial', Circulation, vol. 99, no. 18, pp. 2371-2377.
Mahaffey, Kenneth W. ; Harrington, Robert A. ; Simoons, Maarten L. ; Granger, Christopher B. ; Graffagnino, Carmelo ; Alberts, Mark J. ; Laskowitz, Daniel T. ; Miller, Julie M. ; Sloan, Michael A. ; Berdan, Lisa G. ; MacAulay, Cynthia M. ; Lincoff, A. Michael ; Deckers, Jaap ; Topol, Eric J. ; Califf, Robert M. / Stroke in patients with acute coronary syndromes : Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial. In: Circulation. 1999 ; Vol. 99, No. 18. pp. 2371-2377.
@article{a42196b901854eed88e3296f61d6b80f,
title = "Stroke in patients with acute coronary syndromes: Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial",
abstract = "Background - The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates. Methods and Results - We studied the 10 948 patients with acute coronary syndromes without persistent ST-segment elevation who were randomly assigned to placebo or the platelet glycoprotein IIb/IIIa receptor inhibitor eptifibatide in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial to determine stroke fates, stroke types, clinical outcomes in patients with stroke, and independent baseline clinical predictors for nonhemorrhagic stroke. Stroke occurred in 79 (0.7{\%}) patients, with 66 (0.6{\%}) nonhemorrhagic, 6 intracranial hemorrhages, 3 cerebral infarctions with hemorrhagic conversion, and 4 of uncertain cause. There were no differences in stroke rates between patients who received placebo and those assigned high-dose eptifibatide (odds ratios and 95{\%} confidence intervals 0.82 [0.59, 1.14] and 0.70 [0.49, 0.99], respectively). Of the 79 patients with stroke, 17 (22{\%}) died within 30 days, and another 26 (32{\%}) were disabled by hospital discharge or 30 days, whichever came first. Higher heart rate was the most important baseline clinical predictor of nonhemorrhagic stroke, followed by older age, prior anterior myocardial infarction, prior stroke or transient ischemic attack, and diabetes mellitus. These factors were used to develop a simple scoring nomogram that can predict the risk of nonhemorrhagic stroke. Conclusions - Stroke was an uncommon event in patients with acute coronary syndromes in the PURSUIT trial. These strokes are, however, associated with substantial morbidity and mortality rates. The majority of strokes were of nonhemorrhagic causes. Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed. We developed a useful nomogram for assigning baseline nonhemorrhagic stroke risk in this patient population.",
keywords = "Coronary disease, Glycoproteins, Myocardial infarction, Receptors, Stroke",
author = "Mahaffey, {Kenneth W.} and Harrington, {Robert A.} and Simoons, {Maarten L.} and Granger, {Christopher B.} and Carmelo Graffagnino and Alberts, {Mark J.} and Laskowitz, {Daniel T.} and Miller, {Julie M.} and Sloan, {Michael A.} and Berdan, {Lisa G.} and MacAulay, {Cynthia M.} and Lincoff, {A. Michael} and Jaap Deckers and Topol, {Eric J.} and Califf, {Robert M.}",
year = "1999",
month = "5",
day = "11",
language = "English (US)",
volume = "99",
pages = "2371--2377",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Stroke in patients with acute coronary syndromes

T2 - Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial

AU - Mahaffey, Kenneth W.

AU - Harrington, Robert A.

AU - Simoons, Maarten L.

AU - Granger, Christopher B.

AU - Graffagnino, Carmelo

AU - Alberts, Mark J.

AU - Laskowitz, Daniel T.

AU - Miller, Julie M.

AU - Sloan, Michael A.

AU - Berdan, Lisa G.

AU - MacAulay, Cynthia M.

AU - Lincoff, A. Michael

AU - Deckers, Jaap

AU - Topol, Eric J.

AU - Califf, Robert M.

PY - 1999/5/11

Y1 - 1999/5/11

N2 - Background - The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates. Methods and Results - We studied the 10 948 patients with acute coronary syndromes without persistent ST-segment elevation who were randomly assigned to placebo or the platelet glycoprotein IIb/IIIa receptor inhibitor eptifibatide in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial to determine stroke fates, stroke types, clinical outcomes in patients with stroke, and independent baseline clinical predictors for nonhemorrhagic stroke. Stroke occurred in 79 (0.7%) patients, with 66 (0.6%) nonhemorrhagic, 6 intracranial hemorrhages, 3 cerebral infarctions with hemorrhagic conversion, and 4 of uncertain cause. There were no differences in stroke rates between patients who received placebo and those assigned high-dose eptifibatide (odds ratios and 95% confidence intervals 0.82 [0.59, 1.14] and 0.70 [0.49, 0.99], respectively). Of the 79 patients with stroke, 17 (22%) died within 30 days, and another 26 (32%) were disabled by hospital discharge or 30 days, whichever came first. Higher heart rate was the most important baseline clinical predictor of nonhemorrhagic stroke, followed by older age, prior anterior myocardial infarction, prior stroke or transient ischemic attack, and diabetes mellitus. These factors were used to develop a simple scoring nomogram that can predict the risk of nonhemorrhagic stroke. Conclusions - Stroke was an uncommon event in patients with acute coronary syndromes in the PURSUIT trial. These strokes are, however, associated with substantial morbidity and mortality rates. The majority of strokes were of nonhemorrhagic causes. Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed. We developed a useful nomogram for assigning baseline nonhemorrhagic stroke risk in this patient population.

AB - Background - The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates. Methods and Results - We studied the 10 948 patients with acute coronary syndromes without persistent ST-segment elevation who were randomly assigned to placebo or the platelet glycoprotein IIb/IIIa receptor inhibitor eptifibatide in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial to determine stroke fates, stroke types, clinical outcomes in patients with stroke, and independent baseline clinical predictors for nonhemorrhagic stroke. Stroke occurred in 79 (0.7%) patients, with 66 (0.6%) nonhemorrhagic, 6 intracranial hemorrhages, 3 cerebral infarctions with hemorrhagic conversion, and 4 of uncertain cause. There were no differences in stroke rates between patients who received placebo and those assigned high-dose eptifibatide (odds ratios and 95% confidence intervals 0.82 [0.59, 1.14] and 0.70 [0.49, 0.99], respectively). Of the 79 patients with stroke, 17 (22%) died within 30 days, and another 26 (32%) were disabled by hospital discharge or 30 days, whichever came first. Higher heart rate was the most important baseline clinical predictor of nonhemorrhagic stroke, followed by older age, prior anterior myocardial infarction, prior stroke or transient ischemic attack, and diabetes mellitus. These factors were used to develop a simple scoring nomogram that can predict the risk of nonhemorrhagic stroke. Conclusions - Stroke was an uncommon event in patients with acute coronary syndromes in the PURSUIT trial. These strokes are, however, associated with substantial morbidity and mortality rates. The majority of strokes were of nonhemorrhagic causes. Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed. We developed a useful nomogram for assigning baseline nonhemorrhagic stroke risk in this patient population.

KW - Coronary disease

KW - Glycoproteins

KW - Myocardial infarction

KW - Receptors

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0033545829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033545829&partnerID=8YFLogxK

M3 - Article

VL - 99

SP - 2371

EP - 2377

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 18

ER -